Asset profile
glasmacinal
Small molecule
Evidence outlook · lead readout
NCT05572333 · Chronic Obstructive Pulmonary Disease, COPD
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05572333: The study randomized 61 participants to EP395 or matched placebo and kept participants and investigators blinded. Its primary outcomes were safety assessments rather than clinical improvement, and no primary-endpoint results are available, so the evidence remains limited.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.